LINC Reveals Lucas System Is Effective In Pre-Hospital Cardiac Arrest Patients
At the European Society of Cardiology (ESC) Congress 2013, held from August 31 to September 4, in Amsterdam, the Netherlands, main results from the large randomised LINC study which compared the effectiveness of Physio-Control's Lucas mechanical chest compression system with high quality manual chest compressions were presented. The LINC study showed similar short-term survival rates for Lucas (23.6%) and manual (23.7%) chest compressions. At six-months, 8.5% of the patients treated with Lucas were alive with good neurological outcomes compared with 7.6% in the manual group.
The study provides evidence that sudden cardiac arrest patients can be effectively treated using Lucas mechanical chest compressions. The Lucas chest compression system provides several additional benefits to resuscitation care:
â¢ Frees rescuers to provide other life-saving therapies without the limitations or difficulties of manual cardiopulmonary resuscitation (CPR).
â¢ Standardises the quality of chest compressions adhering to the European Resuscitation Council and American Heart Association Guidelines for CPR depth, rate and recoil.
â¢ Allows for effective CPR during patient transportation, while improving rescuer safety.
â¢ Used in the catheterisation laboratory to reopen blocked arteries during CPR.
The LINC study led and presented by Professor Sten Rubertsson from Uppsala University, Sweden, included 2,589 out-of-hospital cardiac arrest patients in Europe over five years, from 2008 to 2013. It is one of the largest controlled, envelope randomised trials for out-of-hospital cardiac arrest in history. The patients were randomised to either the Lucas device receiving mechanical chest compressions with defibrillation provided during ongoing compressions, or to manual chest compressions according to the European Resuscitation Council and American Heart Association Guidelines for CPR. The results are encouraging, with the vast majority of survivors having good neurological status at six months, 99% in the Lucas group, 94% in the manual group. Moreover, the overall survival rate is high considering the study excluded the most viable groups; the patients defibrillated before EMS arrival and EMS witnessed cardiac arrests that were successfully defibrillated with the first shock.
Lucas is a uniquely designed device with respect to the rate and depth of compressions delivered, ease of use, and the manner in which force is exerted on the chest. The combination of these characteristics contribute to device efficacy, therefore the findings of this study may not apply to other chest compression devices. The mechanical CPR device has shown to maintain blood circulation better than manual CPR, to increase operational efficacy and safety, and to improve the opportunities to save cardiac arrest patients. Lucas has shown to save lives by allowing for simultaneous percutaneous coronary intervention during CPR or work as a bridge to other therapies. Lucas was launched in 2003, and is currently available in over 40 markets globally.